RECRUITING

Testing Gene PilotLX With Latinx Cancer Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.

Official Title

Testing the Efficacy of an eHealth Decision Support Tool to Help Latinx Cancer Patients Make Informed Decisions About Tumor Genomic Testing

Quick Facts

Study Start:2025-05-01
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06476938

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. diagnosed with solid tumor cancers
  2. 2. speak/read English or Spanish;
  3. 3. can provide informed consent.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Michael J Hall, MD, MS
CONTACT
215-728-2861
michael.hall@fccc.edu
Sarah B Bass, PhD, MPH
CONTACT
215-204-5110
sbass@temple.edu

Principal Investigator

Michael J Hall, MD,MS
PRINCIPAL_INVESTIGATOR
Fox Chase Cancer Center
Sarah B Bass, PhD, MPH
PRINCIPAL_INVESTIGATOR
Temple University
Tracey A Revenson, PhD
PRINCIPAL_INVESTIGATOR
Hunter College of City University of New York

Study Locations (Sites)

MD Anderson Cancer Center at Cooper
Camden, New Jersey, 08103
United States
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Temple University Hospital
Philadelphia, Pennsylvania, 19122
United States

Collaborators and Investigators

Sponsor: Fox Chase Cancer Center

  • Michael J Hall, MD,MS, PRINCIPAL_INVESTIGATOR, Fox Chase Cancer Center
  • Sarah B Bass, PhD, MPH, PRINCIPAL_INVESTIGATOR, Temple University
  • Tracey A Revenson, PhD, PRINCIPAL_INVESTIGATOR, Hunter College of City University of New York

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-01
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2025-05-01
Study Completion Date2027-12-31

Terms related to this study

Keywords Provided by Researchers

  • eHealth decision tool
  • Hispanic/Latino
  • Tumor Genomic Profiling

Additional Relevant MeSH Terms

  • Cancer